These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes. Cervantes-Gomez F; Kumar Patel V; Bose P; Keating MJ; Gandhi V Leukemia; 2016 Aug; 30(8):1803-4. PubMed ID: 27198052 [No Abstract] [Full Text] [Related]
10. Population Pharmacokinetics and Exposure Response Assessment of CC-292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia. Li Y; Ramírez-Valle F; Xue Y; Ventura JI; Gouedard O; Mei J; Takeshita K; Palmisano M; Zhou S J Clin Pharmacol; 2017 Oct; 57(10):1279-1289. PubMed ID: 28543084 [TBL] [Abstract][Full Text] [Related]
11. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Walter HS; Rule SA; Dyer MJ; Karlin L; Jones C; Cazin B; Quittet P; Shah N; Hutchinson CV; Honda H; Duffy K; Birkett J; Jamieson V; Courtenay-Luck N; Yoshizawa T; Sharpe J; Ohno T; Abe S; Nishimura A; Cartron G; Morschhauser F; Fegan C; Salles G Blood; 2016 Jan; 127(4):411-9. PubMed ID: 26542378 [TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up and future direction on the management of chronic lymphocytic leukemia/small lymphocytic leukemia. Hanna KS; Fijalka A; Watson I; Brown O; Ojulu A J Oncol Pharm Pract; 2022 Dec; 28(8):1869-1884. PubMed ID: 35635742 [TBL] [Abstract][Full Text] [Related]
13. A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity. Eda H; Santo L; Cirstea DD; Yee AJ; Scullen TA; Nemani N; Mishima Y; Waterman PR; Arastu-Kapur S; Evans E; Singh J; Kirk CJ; Westlin WF; Raje NS Leukemia; 2014 Sep; 28(9):1892-901. PubMed ID: 24518207 [TBL] [Abstract][Full Text] [Related]
15. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor. Kriegsmann K; Kriegsmann M; Witzens-Harig M Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636 [TBL] [Abstract][Full Text] [Related]
16. Second-Generation Bruton's Tyrosine Kinase Inhibitors: Simply the Best Treatments for Chronic Lymphocytic Leukemia? Stephens DM J Clin Oncol; 2021 Nov; 39(31):3419-3422. PubMed ID: 34310198 [No Abstract] [Full Text] [Related]
17. The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia. Molica S Expert Rev Hematol; 2013 Oct; 6(5):543-6. PubMed ID: 24083545 [TBL] [Abstract][Full Text] [Related]
18. Invasive fungal infections in patients treated with Bruton's tyrosine kinase inhibitors. Dunbar A; Joosse ME; de Boer F; Eefting M; Rijnders BJA Neth J Med; 2020 Sep; 78(5):294-296. PubMed ID: 33093256 [TBL] [Abstract][Full Text] [Related]
19. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma. Tam CS Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894 [No Abstract] [Full Text] [Related]
20. Role of Bruton's tyrosine kinase in B cells and malignancies. Pal Singh S; Dammeijer F; Hendriks RW Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]